169 related articles for article (PubMed ID: 38501850)
1. Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current Approaches.
Hardinger KL; Brennan DC
Ann Pharmacother; 2024 Mar; ():10600280241237534. PubMed ID: 38501850
[TBL] [Abstract][Full Text] [Related]
2. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
Razonable RR
Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
[TBL] [Abstract][Full Text] [Related]
3. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
4. New Perspectives on Antimicrobial Agents: Maribavir.
Halpern-Cohen V; Blumberg EA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0240521. PubMed ID: 35916518
[TBL] [Abstract][Full Text] [Related]
5. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J; Ramil C; Green M
Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic developments in cytomegalovirus retinitis.
Hoffman VF; Skiest DJ
Expert Opin Investig Drugs; 2000 Feb; 9(2):207-20. PubMed ID: 11060672
[TBL] [Abstract][Full Text] [Related]
7. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.
Plosker GL; Noble S
Drugs; 1999 Aug; 58(2):325-45. PubMed ID: 10473024
[TBL] [Abstract][Full Text] [Related]
8. Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations.
Kleiboeker HL; Descourouez JL; Schulz LT; Mandelbrot DA; Odorico JS; Rice JP; Saddler CM; Smith JA; Jorgenson MR
Ann Pharmacother; 2023 May; 57(5):597-608. PubMed ID: 36003036
[TBL] [Abstract][Full Text] [Related]
9. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
[TBL] [Abstract][Full Text] [Related]
10. New Treatment Options for Refractory/Resistant CMV Infection.
Walti CS; Khanna N; Avery RK; Helanterä I
Transpl Int; 2023; 36():11785. PubMed ID: 37901297
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus.
Gandhi RG; Kotton CN
Ther Clin Risk Manag; 2022; 18():223-232. PubMed ID: 35308097
[TBL] [Abstract][Full Text] [Related]
12. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions.
Razonable RR
Curr Pharm Des; 2020; 26(28):3497-3506. PubMed ID: 32473617
[TBL] [Abstract][Full Text] [Related]
14. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
[TBL] [Abstract][Full Text] [Related]
16. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Meesing A; Razonable RR
Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
Cvetković RS; Wellington K
Drugs; 2005; 65(6):859-78. PubMed ID: 15819597
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Treatment.
Tan BH
Curr Treat Options Infect Dis; 2014; 6(3):256-270. PubMed ID: 25999800
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
Razonable RR
World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
[TBL] [Abstract][Full Text] [Related]
20. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]